182 related articles for article (PubMed ID: 12063809)
1. Direct thrombin inhibitors for percutaneous coronary intervention in the current era of platelet glycoprotein IIb/IIIa inhibition.
Reginelli JP; Chew D
J Interv Cardiol; 2002 Apr; 15(2):141-6. PubMed ID: 12063809
[No Abstract] [Full Text] [Related]
2. Should bivalirudin replace heparin during percutaneous coronary interventions?
Antman EM
JAMA; 2003 Feb; 289(7):903-5. PubMed ID: 12588276
[No Abstract] [Full Text] [Related]
3. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
Lincoff AM; Bittl JA; Harrington RA; Feit F; Kleiman NS; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Kereiakes DJ; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
JAMA; 2003 Feb; 289(7):853-63. PubMed ID: 12588269
[TBL] [Abstract][Full Text] [Related]
4. Provisional use of glycoprotein IIb/IIIa inhibitors in the era of dual antiplatelet therapy--do "bailouts" pay off?
Jeremias A; Gruberg L
J Invasive Cardiol; 2009 Jun; 21(6):264-5. PubMed ID: 19494401
[No Abstract] [Full Text] [Related]
5. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).
Chew DP; Lincoff AM; Gurm H; Wolski K; Cohen DJ; Henry T; Feit F; Topol EJ;
Am J Cardiol; 2005 Mar; 95(5):581-5. PubMed ID: 15721095
[TBL] [Abstract][Full Text] [Related]
6. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
[TBL] [Abstract][Full Text] [Related]
7. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
8. Direct thrombin inhibitors (part 2 of 2).
Arora UK; Dhir M
J Invasive Cardiol; 2005 Feb; 17(2):85-91. PubMed ID: 15687531
[No Abstract] [Full Text] [Related]
9. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
Feldman DN; Wong SC; Bergman G; Minutello RM
J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400
[TBL] [Abstract][Full Text] [Related]
10. Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
Pinto DS; Sperling RT; Tu TM; Cohen DJ; Carrozza JP
Catheter Cardiovasc Interv; 2003 Jan; 58(1):65-8. PubMed ID: 12508198
[TBL] [Abstract][Full Text] [Related]
11. [Direct thrombin antagonists].
Lankes W; Fleischer K; Gulba DC
Herz; 2001 Apr; 26 Suppl 1():46-52. PubMed ID: 11349627
[TBL] [Abstract][Full Text] [Related]
12. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
[TBL] [Abstract][Full Text] [Related]
13. The role of thrombin inhibition during percutaneous coronary intervention.
Wittkowsky AK
Pharmacotherapy; 2002 Jun; 22(6 Pt 2):97S-104S. PubMed ID: 12064571
[TBL] [Abstract][Full Text] [Related]
14. Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
Topol EJ
Am J Cardiol; 1998 Oct; 82(8B):63P-68P. PubMed ID: 9809894
[TBL] [Abstract][Full Text] [Related]
15. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ;
JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903
[TBL] [Abstract][Full Text] [Related]
16. Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.
Kwa AT; Rogers JH
J Interv Cardiol; 2008 Apr; 21(2):107-17. PubMed ID: 18248357
[TBL] [Abstract][Full Text] [Related]
17. Which antithrombotic to use during PCI?
Jolly SS; Yusuf S
Eur Heart J; 2010 Mar; 31(5):522-4. PubMed ID: 20150323
[No Abstract] [Full Text] [Related]
18. Contemporary use of antiplatelet therapies in percutaneous coronary interventions.
Saw J; Moliterno DJ
Coron Artery Dis; 2003 Aug; 14(5):373-80. PubMed ID: 12878902
[No Abstract] [Full Text] [Related]
19. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.
Campbell KR; Mahaffey KW; Lewis BE; Weitz JI; Berkowitz SD; Ohman EM; Califf RM
J Invasive Cardiol; 2000 Dec; 12 Suppl F():14F-9. PubMed ID: 11156729
[No Abstract] [Full Text] [Related]
20. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).
Lincoff AM; Kleiman NS; Kottke-Marchant K; Maierson ES; Maresh K; Wolski KE; Topol EJ
Am Heart J; 2002 May; 143(5):847-53. PubMed ID: 12040347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
